Displaying 1 - 20 of 1633
FTC Issues Letters Warning Hospitals Against Deceptive Pricing Practices
Statement Regarding Fairfield Medical Center’s Sale to Adena Health
FTC Approves Final Consent Order in Ascension Health-AmSurg Deal
FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
Caremark and Zinc Health Services; Analysis of Proposed Agreement Containing Consent Order To Aid Public Comment
FTC Secures Major Settlement with Caremark, Resolving Antitrust Case Against Second Drug Middleman
Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
On February 4, 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts, Inc., and its affiliated entities (collectively “ESI”). The settlement requires ESI to adopt fundamental changes to its business practices that increase transparency, are expected to drive down patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years, bring millions of dollars in new revenue to community pharmacies each year, and advance the Trump Administration’s key healthcare priorities.
On July 14, 2026, the Federal Trade Commission secured a settlement agreement Caremark Rx LLC and Zinc Health Services LLC (collectively Caremark) .
Caremark has agreed to a settlement agreement that requires the PBM to adopt changes to its business practices to drive down patients’ out-of-pocket costs, increase transparency and ensure community pharmacies are treated fairly.
FTC Secures $12 Million in Penalties for Pre-Merger Reporting Act Violations
United States v. Edwards LifeSciences Corp. and Genesis MedTech Group Ltd
The Federal Trade Commission secured $12 million in penalties to settle charges alleging that Edwards Lifesciences Corp. acquired medical device maker JC Medical from Genesis MedTech Group Limited without complying with the notification and waiting period requirements of the Hart-Scott-Rodino Act (HSR).
Under the terms of a proposed final judgment Edwards, including former Genesis subsidiary JC Medical, will pay a $10 million penalty. Genesis will pay a $2 million penalty. Edwards will also be subject to additional terms including prior notice requirements. The combined $12 million penalty is the largest ever for failing to make an HSR filing.
Aurobindo and Lannett; Analysis of Proposed Agreement Containing Consent Orders To Aid Public Comment
FTC Files Amicus Brief to Protect Consumers from Pharmaceutical Monopolies
CareFirst of Maryland, et al., Plaintiffs-Appellants, v. Johnson & Johnson, et al., Defendants-Appellees.
FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal
Aurobindo-Lannett, In the Matter of
The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.
WPATH, FTC v.
The Federal Trade Commission, along with Alaska, Iowa, Nebraska and Texas, today filed a lawsuit against the World Professional Association for Transgender Health (WPATH), alleging the organization has provided the means for medical providers to make false and unsubstantiated claims to parents in order to sell pediatric medical transition services.